{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:21Z","timestamp":1788419781811,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While CAR-T cell therapy has transformed outcomes in B-cell malignancies, most genomic insights originate from clinical trials. There is a paucity of data describing molecular changes during CAR-T manufacturing in real-world practice, particularly for non-US CAR constructs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was an observational study conducted at a tertiary care center in India where a total of 4 set of paired samples comprising leukapheresis starting material (n=4) and the corresponding final CAR-T cell product (n=4) were analyzed. Analysis was done using NanoString nCounter\n                      <jats:sup>\u00ae<\/jats:sup>\n                      platform with a targeted immune-oncology panel comprising 750 genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparative gene expression analysis between CAR-T product and leukapheresis sample revealed significant upregulation of genes associated with cell proliferation (MKI67, BUB1), cytokine responsiveness (IL2RA, IL12RB2, CISH), metabolic fitness (PHGDH, PSAT1), and effector differentiation (IRF4, BATF3, LIF) in final product as compared to leukapheresis sample. Concurrent downregulation of innate immune and myeloid lineage genes (CD14, FCGR3A\/B, FCAR, CYBB, FPR1, LILRA5, TYROBP, S100A12) along with reduced expression of inflammatory mediators (FOS, DUSP1, S100A12) suggests a controlled activation state that may limit baseline inflammatory priming and effective enrichment of adaptive T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Indigenous CAR-T manufacturing processes induce significant transcriptomic remodeling and reflects a highly proliferative and cytokine-responsive CAR-T phenotype associated with improved functional fitness. These findings may reflect a baseline framework for CAR-T genomic characterization in real-world clinical settings to explore outcome-related analyses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1912690","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:01Z","timestamp":1788417781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world insights into genomic reprogramming during CAR-T cell manufacturing in India"],"prefix":"10.3389","volume":"17","author":[{"given":"Nupur","family":"Das","sequence":"first","affiliation":[{"name":"Department of Pathology, School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusum","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Katharia","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Pabbi","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravas","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soni","family":"Morya","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Amrita Vishwa Vidyapeetham","place":["Faridabad, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological Malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00753","article-title":"Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors","volume":"9","author":"Gerber","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19001","article-title":"Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas","volume":"203","author":"Gao","year":"2023","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2023.103828","article-title":"Leukapheresis for CAR-T cell production and therapy","volume":"62","author":"Pessach","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011807","article-title":"Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing","volume":"13","author":"Yu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1182\/blood-2023-189441","article-title":"Autophagy inhibition prevents CAR-T exhaustion and terminal differentiation via TCF7 accumulation","volume":"142","author":"Teng","year":"2023","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1508","article-title":"Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T-cell receptor lineages","volume":"12","author":"Wilson","year":"2022","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116129","article-title":"The transcription factor BATF pioneers the differentiation program of effector CD8+ T cells through the interaction with IRF4","volume":"44","author":"Fujisawa","year":"2025","journal-title":"Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-025-01205-y","article-title":"PHGDH at the crossroads: metabolic plasticity, metastatic paradoxes, and therapeutic reconnaissance in cancer","volume":"33","author":"Hao","year":"2026","journal-title":"J BioMed Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3888","article-title":"Dissecting the tumor-immune landscape in chimeric antigen receptor T-cell therapy: Key challenges and opportunities for a systems immunology approach","volume":"26","author":"Chen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1912690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:02Z","timestamp":1788417782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1912690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2026.1912690"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1912690","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1912690"}}